RANKL/RANK/OPG: Key therapeutic target in bone oncology

Current Drug Discovery Technologies

Volumn 5, Issue 3, 2008, Pages 263-268

  Ando, Kosei ^a   Mori, Kanji ^a   Rédini, Francoise ^b,c   Heymann, Dominique ^b,c  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b INSERM   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

Bone metastasis; Cancer; OPG; Osteoclast; Osteosarcoma; RANK; RANKL; Vicious cycle

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

BONE CANCER; BONE METASTASIS; BONE REMODELING; CELL MIGRATION; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG TARGETING; HOMEOSTASIS; HUMAN; MICROENVIRONMENT; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; QUALITY OF LIFE; REGULATORY MECHANISM; REVIEW; TUMOR CELL;

EID: 51349111849     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016308785739857     Document Type: Review

References (104)

1. Mundy G.R.: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584, (2002).
2. Coleman R.E.: Skeletal complications of malignancy. Cancer 80, 1588, (1997).
3. Coleman R.E.: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27, 165, (2001).
4. Meyers P.A., Schwartz C.L., Krailo M., Kleinerman E.S., Betcher D., Bernstein M.L., Conrad E., Ferquson W., et al.: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol. 23(9), 2004, (2005). ** The pivotal clinical trial in osteosarcoma with L-MTP-PE that demonstrated safety, efficacy of L-MTP-PE.
5. Bielack S.S., Kempf-Bielack B., Delling G., Exner G.U., Fleqe S., Helmke K., Kutz R., et al.: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. 20(3), 776, (2002).
6. Hawkins D.S., Arndt C.A.: Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 98(11), 2447, (2003).
7. Anderson P.: Osteosarcoma relapse: expect the worst, but hope for the best. Pediatr. Blood. Cancer 47(3), 231, (2006).
8. Felix R., Hofstetter W., Cecchini M.G.,: Recent developments in the understanding of the pathophysiology of osteopetrosis. Eur. J. Endocrinol. 134, 143, (1996).
9. Karsent G., Wagner E.F.: Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2, 389, (2002).
10. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597, (1998).
11. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165, (1998).
12. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., et al.: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175, (1997).
13. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309, (1997).
14. Tat SK., Padrines M., Theoleyre S., Couillaud-Battaglia S., Heymann D., Rédini F., Fortun Y.: OPG/membra nous-RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone 39, 706, (2006).
15. Goltzman D.: Osteolysis and cancer, J. Clin. Invest. 107, 1219, (2001).
16. Brown J.M., Corey E., Lee Z.D., True L.D., Yun T.J., Tondravi M., Vessella R.L.: Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57, 611, (2001).
17. Granchi D., Amato L, Battistelli L., Avnet S., Capaccioli S., Papucci L., Donnini M., Pellacani A., et al.: In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells. Int. J. Cancer 111, 829, (2004).
18. Farrugia A.N., Atkins G.J., To L.B., Pan B., Horvath N., Kostakis P., Findlay D.M, Bardy P., et al.: Receptor activator of nuclear facto rkappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res. 63, 5438, (2003).
19. Nosaka K., Miyamoto T., Sakai T., Mitsuya H., Suda T., Matsuoka M.: Mechanism of hypercalcemia in adult T-cell leukemia: Overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 99, 634, (2002).
20. Chen G., Sircar K., Aprikian A., Potti A., Goltzman D., Rabbani S.A.: Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107, 289, (2006).
21. Perez-Martinez F.C., Alonso V., Sarasa J.L., Nam-Cha S.G., Vela-Navarrete R., Manzarbeitia F., Callahora F.J., Esbrit P.: Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: Relative changes of PTHrP and its PTH1 receptor, osteoprotegerin and receptor activator of nuclear factor kb ligand. J. Clin. Pathol. 60(3), 290, (2007).
22. Michigami T., Ihara-Watanabe M., Yamazaki M., Ozono K.: Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res. 61, 1637, (2001).
23. Lee Y, Schwarz E., Davies M., Jo M., Gates J., Wu J., Zhang X., Lieberman J.R.: Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J. Orthop. Res. 21, 62, (2003).
24. Holen I., Cross S.S., Neville-Webbe H.L., Cross N.A., Balasubramanian S.P., Croucher P.I., Evans C.A., Lippitt J.M., et al.: Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo a role in tumour cell survival? Breast. Cancer Res. Treat. 92, 207, (2005).
25. Holen I., Croucher P.I., Hamdy F.C., Eaton C.L.: Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62, 1619, (2002).
26. Van Poznak C., Cross S.S., Saggese M., Hudis C., Panageas K.S., Norton L., Coleman R.E., Holen I.: Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor {kappa}B ligand (RANKL) in human breast tumours. J. Clin. Pathol. 59, 56, (2006).
27. Grano M., Mori G., Minielli V., Cantatore F.P., Colucci S., Zallone A.Z.: Breast cancer cell line MDA-23I stimulates osteoclastogenesis and bone resorption in human osteoclasts. Biochem. Biophys. Res. Commun. 270, 1097, (2000).
28. Wani M.R., Fuller K., Kim N.S., Choi Y., Chambers T.: Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 140, 1927, (1999).
29. Guise T.A., Yin J.J., Taylor S.D., Kumagai Y., Dallas M., Boyce B.F., Yoneda T., Mundy G.R.: Evidence for a causal role of parathyroid hormonerelated protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. 98, 1544, (1996).
30. Shen X., Falzon M.: PTH-related protein modulates PC-3 prostate cancer cell adhesion and integrin subunit profile. Mol. Cell. Endocrinol. L99, 165, (2003).
31. Pfeilschifter J., Mundy G.R.: Modulation of type β transforming growth factor activity in bone cultures by osteotropic hormones. Proc. Natl. Acad. Sci. USA 84, 2024, (1987).
32. Halvorson K.G., Sevcik M.A., Ghilardi J.R., Rosol T.J., Mantyh P.W.: Similarities and differences in tumor growth, skeletal remodeling and pain an osteolytic and osteoblastic model of bone cancer. Clin. J. Pain 22, 587, (2006).
33. Atkins G.J., Hayes D.R., Graves S.E., Evadokiou A., Hay S., Bouralexis S., Findlay D.M.: Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J. Bone Miner. Res. 15, 640, (2000).
34. Wittrant Y., Lamoureux F., Mori K., Riet A., Kamijo A., Hey maim D., Rédini F.: RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int. J. Oncol. 28, 261, (2006).
35. Mori K., Le Goff B., Berreur M., Riet A., Moreau A., Blanchard F., Chevalier C., Guisle-Marsollier I., et al.: Human osteosarcoma cells express functional receptor activator nuclearfactor-kappaB. J. Pathol. 211, 555, (2007).
36. Jones D.H., Nakashima T., Sanchez O.H., Kozieradzki I., Komarova S.V., Sarosi I., Morony S., Rubin E., et al.: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692, (2006).
37. Thomas R.J., Guise T.A., Yin J.J., Elliott J., Horwood N.J., Martin T.J., Gillespie M.T.: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140, 4451, (1999).
38. Tometsko M., Armstrong A., Miller R., Jones J., Chaisson M., Branstetter D.: RANK ligand directly induces osteoclastogenic, angiogenic, chemoat-tractive and invasive factors on RANK-expressing human cancer cells MDAMB-231 and PC3. J. Bone Miner. Res. 19, S25, (2004).
39. Mori K., Berreur M., Blanchard F., Chevalier C., Guisle-Marsollier I., Masson M., Rédini F., Heymann D.: Receptor activator nuclear factor-κB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol. Rep. 18(6), 1365, (2007).
40. Bhatia P., Sanders M.M., Hansen M.F.: Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin. Cancer. Res. 11, 162, (2005).
41. Mori K., Goff B.L., Charrier C., Battaglia S., Heymann D., Rédini F.: DU145 human prostate cancer cells express functional receptor activator of NFκB: New insights in the prostate cancer bone metastasis process. Bone 40, 981, (2007).
42. Arron J.R., Choi Y.: Bone versus immune system. Nature 408, 535, (2000).
43. Zheng M.H., Fan Y., Wysocki S., Lau A.T.T., Robertson T., Beilharz M., Wood D.J., Papadimitriou J.M.: Gene expression of transforming growth factor-β and its type II receptor in giant cell tumor of bone. Am. J. Pathol. 145, 1095, (1994).
44. Golding S.R., Roelke M.S., Petrison K.K., Bhan A.K.: Human giant cell tumor of bone: identification and characterisation of cell types. J. Clin. Invest. 79, 483, (1987).
45. Wulling M., Kaiser E.: The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum. Pathol. 34, 983, (2003).
46. Joyner C.J., Quinn J.M., Triffit J.T., Owen M.E., Athanasou N.A.: Phenotypic characterisation of mononuclear and multinucleated cells of giant cell tumor of bone. Bone Miner. 16, 37, (1992).
47. James I.E., Dodds R.A., Olivera D.L., Nuttall M.E., Gowen M.: Human osteoclastoma-derived stromal cells: correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo. J. Bone. Miner. Res. 11, 1453, (1996).
48. Boyle W.J., Simonet S.W., Lacey D.L.: Osteoclast differentiation and activation. Nature 423, 337, (2003).
49. Golding S.R., Roelke M.S., Petrison K.K., Bhan A.K.: Human giant cell tumor of bone: identification and characterisation of cell types. J. Clin. Invest. 79, 483, (1987).
50. Athanasou N.A., Bliss E., Garter K.C., Heryet A., Wood C.G., McGee J.O.D.: An immunohistological study of giant cell tumor of bone: evidence for an osteoclast origin of the giant cells. J. Pathol. 147, 153, (1985).
51. Zheng M.H., Siu P., Papadimitriou J.M., Wood D.J., Murch A.: Telomeric fusion is a major cytogenetic aberration of spindle-shaped mononuclear cells derived from giant cell tumor of bone. Pathology 31, 373, (1999).
52. Zheng M.H., Fan Y., Wysocki S., Wood D.J., Papadimitriou J.M.: Detection of mRNA carbonic anhydrase II in human osteoclast-like cells by in situ hybridisation. J. Bone Miner. Res. 8, 113, (1993).
53. Zheng M.H., Fan Y., Smith A., Wysocki S., Papadimitriou J.M., Wood D.J.: Gene expression of monocyte chemoattractant protein-1 in giant cell tumors of bone osteoclastoma: possible involvement in CD681 macrophage- like cell migration. J. Cell Biochem. 70, 121, (1998).
54. Rosai J.: Ackerman 's Surgical Pathology, 8th Ed. Edited by J. Rosai. St. Louis, Mosby, pp. 1957, (1996).
55. Wittrant Y., Theoleyre S., Chipoy C., Padrines M., Blanchard F., Heymann D., Rédini F.: RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochimica. et. Biophysica. Acta 1704. 49, (2004).
56. Huang L., Xu J., Wood D.J., Zheng M.H.: Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappa B in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am. J. Pathol. 156, 761, (2000).
57. Atkins G.J., Bouralexis S., Haynes D.R., Graves S.E., Geary S.M., Evdokiou A., Zannettino A.C., Hay S., et al.: Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 28, 370, (2001).
58. Herzog C.E.: Overview of sarcomas in the adolescent and young adult population. J. Pediatr. Hematol. Oncol. 27(4), 215, (2005).
59. Stiller C.A., Bielack S.S., Jundt G., Steliarova-Foucher E.: Bone tumours in European children and adolescents, 1978. Report from, the Automated Childhood Cancer Information System project. Eur. J. Cancer 42(13), 2124, (2006).
60. Miller C.W., Aslo A., Won A., Tan M., Lampkin B., Koeffler H.P.: Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J. Cancer Res. Clin. Oncol. 122, 559, (1996).
61. Terpos E., Szydlo R., Apprley J.F., Hatjiharissi E., Politou M., Meletis J., Viniou N., Yataganas X., et al.: Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102, 1064, (2003).
62. Grimaud E., Soubigou L., Couillaud S., Coipeau P., Moreau A., Passuti N., Gouin F., Rédini F., et al.: Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am. J. Pathol. 163, 2021, (2003).
63. Lamoureux F., Richard P., Wittrant Y., Battaglia S., Pilet P., Trichet V., Blanchard F., Gouin F., et al.: Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 67(15), 7308, (2007).
64. Wong B.R., Josien R., Lee S.Y., Sauter B., Li H.L., Steinman R.M., Choi Y.: TRANCE [tumor necrosis factor (TNF)-related activation-induced cytokine], a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186, 2075, (1997).
65. Hage W.D., Aboulafia A.J., Aboulafia D.M.: Incidence, location, and diagnostic evaluation of metastatic bone disease. Orthop. Clin. North Am. 31, 515, (2000).
66. Clines G.A., Guise T.A.: Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr. Relat. Cancer 12, 549, (2005).
67. Oyajobi B.O.: Multiple myeloma/hypercalcemia. Arthritis Res. Ther. (9 Suppl. 1), S4, (2007).
68. Mundy G.R., Bertoline D.R.: Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol. 13, 291, (1986).
69. Belch A.R., Bergsagel D.E., Wilson K., O'Reilly S., Wilson J., Sutton D., Pater J., Johnston D., et al.: Effect of daily etidronate on the osteolysis of multiple myeloma. J. Clin. Oncol. 9, 1397, (1991).
70. Kyle R.A., Jowsey J., Kelly P.J., Taves D.R.: Multiple-myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. N. Engl. J. Med. 293, 1334, (1975).
71. Kyle R.A.: Multiple myeloma, review of 869 cases. Mayo Clin. Proc. 50, 29, (1975).
72. Cozzolino F., Torcia M., Aldinucci D., Rubartelli A., Miliani A., Shaw A.R., Lansdorp P.M., Di Guglielmo R.: Production of interleukin-1 by bone marrow myeloma cells. Blood 74(1), 380, (1989).
73. Kawano M., Tanaka H., Ishikawa H., Nobuyoshi M., Iwato K., Asaoku H., Tanabe O., Kuramoto A.: Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood 73(8), 2145, (1989).
74. Choi S.J., Cruz J.C., Craig F., Chung H., Devlin R.D., Roodman G.D., Alsina M.: Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96, 671, (2000).
75. Han J.H., Choi S.J., Kurihara N., Koide M., Oba Y., Roodman G.D.: Macrophage inflammatory protein-lalpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand. Blood 97, 3349, (2001).
76. Abe M., Hiura K., Wilde J., Moriyama K., Hashimoto T., Ozaki S., Wakatsuki S., Kosaka M., et al.: Role for macrophage inflammatory protein (MIP)-lalpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100, 2195, (2002).
77. Bataille R., Jourdan M., Zhang X.G., Klein B.: Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J. Clin. Invest. 84, 2008, (1989).
78. Seidel C., Borset M., Turesson I., Abildgaard N., Sundan A., Waage A.: Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. Blood 91, 806, 2098, (1998).
79. Pearse R.N., Sordillo E.M., Yaccoby S., Wong B.R., Liau D.F., Colman N., Michaeli J., Epstein J., et al.: Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. USA 98(20), 11581, (2001).
80. Giuliani N., Bataille R., Mancini C., Lazzaretti M., Barille S.: Myeloma cells induce imbalance in the osteoprotegerin/ osteoprotegerin ligand system in the human bone marrow environment. Blood 98(13), 3527, (2001).
81. Ries L.A.G., Eisner M.P., Kosary C.L.: SEER cancer statistics review, 1975. Bethesda (MD): National Cancer Institute, (2003).
82. Kakonen S.M., Mundy G.R.: Mechanism of osteolytic bone metastases in breast carcinoma. Cancer 97, 834, (2003).
83. Guise T.A.: Molecular mechanism of osteolytic bone metastases. Cancer 88, 2892, (2000).
84. Landis S.H., Murray T., Bolden S., Wingo P.A.: Cancer statistics, 1999. CA. Cancer J. Clin. 49, 8, (1999).
85. Clarke N.W., McClure J., George N.J.: Morphometric evidence for bone resorption and replacement in prostate cancer. Br. J. Urol. 68, 74, (1991).
86. Garnero P., Buchs N., Zekri J., Rizzoli R., Coleman R.E., Delmas P.D.: Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer 82, 858, (2000).
87. Inoue H., Nishimura K., Oka D., Nakai Y., Shiba M., Tokizane T., Arai Y., Nakayama M., et al.: Prostate cancer mediates osteoclastogenesis through modifferent pathways. Cancer Lett. 223, 121, (2005).
88. Zhang J., Dai J., Qi Y., Lin D.L., Smith P., Strayhorn C., Mizokami A., Fu Z., et al.: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107, 1235, (2001).
89. Zhang J., Dai J., Yao Z., Lu Y., Dougall W., Keller E.T.: Soluble receptor activator of nuclear factor κB Fc diminishes prostate cancer progression in bone. Cancer Res. 63, 7883, (2003).
90. Corey E., Brown L.G., Kiefer J.A., Quinn J.E., Pitts T.E., Blair J.M., Vessella RL.: Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 65, 1710, (2005).
91. Whang P.G., Schwarz E.M., Gamradt S.C., Dougall W.C., Lieberman J.R.: The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J. Orthop. Res. 23, 1475, (2005).
92. Mountzios G., Dimopoulos M.A., Bamias A., Papadopoulos G., Kastritis E., Syrigos K., Pavlakis G., Terpos E.: Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotege.rin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol. 46(2), 221, (2007).
93. Canon J.R., Roudier M., Bryant R., Morony S., Stolina M., Kostenuik P.J., Dougall W.C.: Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse mode! of breast cancer bone metastasis. Clin. Exp. Metastasis 25(2), 119, (2007).
94. Park H.R., Min S.K., Cho H.D., Kim D.H., Shin H.S., Park Y.E.: Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. J. Korean Med. Sci. 18, 541, (2003).
95. Cross S.S., Harrison R.F., Balasubramanian S.P., Lippitt J.M., Evans C.A., Reed M.W.R., Holen I.: Expression of receptor activator nuclear factor-κB ligand (RANKL) and tumor necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, ND their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables. J. Clin. Pathol. 59, 716, (2006).
96. Armstrong A.P., Miller R.E, Jones J.C., Zhang J., Keller E.T., Dougall W.C.: RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68(1), 92, (2008).
97. Li Y., Kucuk O., Hussain M., Abrams J., Cher M.L., Sarkar F.H.: Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-κB(RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res. 66(9), 4816, (2006).
98. Holen I., Shipman C.M.: Role of osteoprotegerin (OPG) in cancer. Clin. Sci. 110, 279, (2006).
99. Hiraga T., Ueda A., Tamura D., Hata K., Ikeda F., Williams P.J., Yoneda T.: Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int. J. Cancer 106, 973 (2003).
100. Paget S.: The distrubution of secondary growths in cancer of the breast. Lancet 1, 571, (1889).
101. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., Capprelli C., Li J., et al.: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304 (1999).
102. Wong B.R., Josien R., Lee S.Y., Sauter B., Li H.L., Steinman R.M., Choi Y.: TRANCE (tumor necrosis factor [TNFJ-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186, 2075, (1997).
103. Schoppet M., Henser S., Ruppert V., Stubig T., Al-Fakhri N., Maisch B. and Hofbauer L.C.: Osteoprotegerin expression in dendritic cells increases with maturation and is NF-kappaB-dependent. J. Cell. Biochem. 100, 1430, (2007).
104. Baud'huin M, Lamoureux F, Duplomb L, Rédini F, Heymann D. Rankl, Rank. Osteoprotegerin: Key Partners of Osteoimmunology And Vascular Diseases. Cell Mol. Life Sci. 64: 2334 (2007).